Literature DB >> 17924232

Procalcitonin in acute myocardial infarction.

Nikolaos Kafkas1, Kiriaki Venetsanou, Sotirios Patsilinakos, Vasilios Voudris, Dionisios Antonatos, Kostas Kelesidis, George Baltopoulos, Peter Maniatis, Dennis V Cokkinos.   

Abstract

OBJECTIVE: Procalcitonin (PCT) is released in severe bacterial infections, sepsis and in infection independent cases such as major surgery, multiple trauma, cardiogenic shock, burns, resuscitation, and after cardiac surgery. The aim of this study was to determine the levels and the kinetics of PCT in AMI and to investigate their possible correlation with the release of IL-6 and CRP. DESIGN-PATIENTS: The study included 60 patients (47 men, 63.2+/-14.8 years) with the diagnosis of AMI at admission. In all patients, serum levels of PCT, IL-6, CK-MB, TnI and CRP were measured at admission, at 3, 6, 12, 24, 48 and 72 h and at the seventh day.
RESULTS: PCT was elevated in all patients with AMI. It was initially detected in serum approximately 2-3 h after the onset of the symptoms. The median value at admission was 1.3 ng/ml (95% CI: 0.89 to 1.80). The value of PCT showed an increase and reached a plateau after 12-24 h. The median value at 24 h was 3.57 ng/ml (95% CI: 2.89 to 4.55). PCT values fell to baseline (<0.5 ng/ml) by the seventh day. PCT was detected in serum earlier than CK-MB or TnI in 56 of the 60 patients (93.3%). The kinetics of PCT was similar to those of CK-MB and TnI. The maximal values of PCT were positively correlated with the maximal values of IL-6 (r = 0.59, P = 0.00) and of CRP (r = 0.65, P = 0.001). The maximal values of IL-6 were positively correlated with max CRP (r = 0.35, P = 0.045).
CONCLUSIONS: PCT could be considered as a novel sensitive myocardial index. Its release in AMI is probably due to the inflammatory process that occurs during AMI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17924232     DOI: 10.1080/17482940701534800

Source DB:  PubMed          Journal:  Acute Card Care        ISSN: 1748-2941


  16 in total

Review 1.  Procalcitonin in acute cardiac patients.

Authors:  Claudio Picariello; Chiara Lazzeri; Serafina Valente; Marco Chiostri; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-09-29       Impact factor: 3.397

2.  Procalcitonin and acute coronary syndromes: a new biomarker for an old disease.

Authors:  Luigi M Biasucci; Gina Biasillo; Antonella Stefanelli
Journal:  Intern Emerg Med       Date:  2009-07-29       Impact factor: 3.397

Review 3.  Biomarkers in acute heart failure--state of the art.

Authors:  Alan S Maisel; Rajiv Choudhary
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

4.  Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia.

Authors:  Oriol Sibila; Eric M Mortensen; Antonio Anzueto; Elena Laserna; Marcos I Restrepo
Journal:  Eur Respir J       Date:  2013-04-18       Impact factor: 16.671

5.  Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention.

Authors:  Claudio Picariello; Chiara Lazzeri; Marco Chiostri; Gianfranco Gensini; Serafina Valente
Journal:  Intern Emerg Med       Date:  2009-07-08       Impact factor: 3.397

Review 6.  Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina.

Authors:  George Tsaknis; Iraklis Tsangaris; Ignatios Ikonomidis; Argirios Tsantes
Journal:  Dis Markers       Date:  2014-06-19       Impact factor: 3.434

7.  Correlation between the serum procalcitonin level and the extension and severity of coronary artery disease in patients with non-ST-segment elevation myocardial infarction.

Authors:  Seyed-Vahid Hashemipour; Hamidreza Pourhosseini; Ali Hosseinsabet
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-05-15

8.  Kinetic of procalcitonin in patients with cardiogenic shock following acute myocardial infarction: preliminary data.

Authors:  C Picariello; C Lazzeri; M Chiostri; G F Gensini; S Valente
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2010

9.  Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction.

Authors:  René P Andrié; Ulrich M Becher; Ricarda Frommold; Vedat Tiyerili; Jan W Schrickel; Georg Nickenig; Jörg O Schwab
Journal:  Crit Care       Date:  2012-08-13       Impact factor: 9.097

Review 10.  Emerging families of biomarkers for coronary artery disease: inflammatory mediators.

Authors:  Josef Yayan
Journal:  Vasc Health Risk Manag       Date:  2013-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.